Advanced in Virilizing Ovarian Tumor

Dr. David L. Watkins

Oncology | Hematology Oncology
400 Rosalind Redfern Grover Pkwy Ste 100, 
Midland, TX 
 (633.8 mi)
Accepting New Patients
Offers Telehealth
Advanced in Virilizing Ovarian Tumor
400 Rosalind Redfern Grover Pkwy Ste 100, 
Midland, TX 
 (633.8 mi)
OverviewInsuranceLocationsClinical Research

Overview

David Watkins is an Oncologist and a Hematologist Oncology provider in Midland, Texas. Dr. Watkins and is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Pleuropulmonary Blastoma, Paget Disease of the Breast, Breast Cancer, and Small Cell Lung Cancer (SCLC). Dr. Watkins is currently accepting new patients.

His clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in TX
Languages Spoken
English
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Moda Health
  •  Friday Health
  •  Oscar
  •  UnitedHealthcare

Locations

400 Rosalind Redfern Grover Pkwy Ste 100, Midland, TX 79701

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials
Similar Doctors
Experienced in Virilizing Ovarian Tumor
Dr. Manmeet S. Mangat
Hematology Oncology | Hospital Medicine | Oncology
Experienced in Virilizing Ovarian Tumor
Dr. Manmeet S. Mangat
Hematology Oncology | Hospital Medicine | Oncology

Texas Oncology PA

400 Rosalind Redfern Grover Pkwy, Suite 100, 
Midland, TX 
 (1.1 mi)
432-687-1949
Languages Spoken:
English, Hindi, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Manmeet Mangat is a Hematologist Oncology specialist and a Hospital Medicine provider in Midland, Texas. Dr. Mangat and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Familial Colorectal Cancer, Paget Disease of the Breast, Lynch Syndrome, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Mangat is currently accepting new patients.

Experienced in Virilizing Ovarian Tumor
Dr. Phillip H. Chae
Hematology Oncology | Oncology | Hematology
Experienced in Virilizing Ovarian Tumor
Dr. Phillip H. Chae
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

400 Rosalind Redfern Grover Pkwy, Suite 100, 
Midland, TX 
 (1.1 mi)
432-687-1949
Experience:
16+ years
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Phillip Chae is a Hematologist Oncology specialist and an Oncologist in Midland, Texas. Dr. Chae has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Chae is currently accepting new patients.

Experienced in Virilizing Ovarian Tumor
Dr. Ashutosh Rastogi
Oncology | Hematology Oncology
Experienced in Virilizing Ovarian Tumor
Dr. Ashutosh Rastogi
Oncology | Hematology Oncology
301 N N St, 
Midland, TX 
 (1.0 mi)
432-685-1559
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Ashutosh Rastogi is an Oncologist and a Hematologist Oncology provider in Midland, Texas. Dr. Rastogi and is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Childhood Iron Deficiency Anemia. Dr. Rastogi is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile